COVID-19 Antigen Test Market Report 2026

The COVID-19 antigen test market size has grown strongly in recent years. It will grow from $7.59 billion in 2025 to $8.14 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to global pandemic outbreak, urgent need for rapid diagnosis, government-led testing initiatives, hospital-based testing reliance, emergency regulatory approvals.

The COVID-19 antigen test market size is expected to see strong growth in the next few years. It will grow to $10.84 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to preparedness for future outbreaks, expansion of decentralized testing, rising infectious disease surveillance, demand for affordable diagnostics, integration with digital health systems. Major trends in the forecast period include expansion of rapid point-of-care testing, growing adoption of home-based testing kits, increased demand for mass screening programs, simplification of sample collection methods, integration with public health surveillance.

The increase in testing rates is expected to drive the growth of the COVID-19 antigen test market in the coming years. Testing rates refer to the frequency at which diagnostic tests, such as those for COVID-19, are conducted within a population over a defined period. As testing rates rise, demand for COVID-19 testing solutions, including antigen tests, also increases. This growing demand directly supports market expansion, as manufacturers and suppliers are required to scale up production and distribution to meet higher testing needs. For example, in October 2023, according to the National Institutes of Health (NIH), a US-based health organization, the total COVID-19 testing rate ranged from 5.13 to 22,386.63 per 1,000 people between October 2022 and October 2023. Therefore, rising testing rates are contributing to the growth of the COVID-19 antigen test market.

Major companies operating in the COVID-19 antigen test market are concentrating on developing innovative solutions, such as rapid at-home multiplex antigen tests, to address the increasing demand for fast, convenient, and accessible diagnosis of respiratory infections. Rapid at-home multiplex antigen tests are diagnostic kits designed to detect multiple pathogens, including COVID-19 and influenza A and B, from a single sample, delivering quick and accurate results at home to support timely isolation, treatment, and reduced strain on healthcare systems. For instance, in May 2024, iHealth Inc., a US-based digital health company, launched its 3-in-1 COVID-19/Flu A and B Rapid Test Kit. This over-the-counter home antigen test provides results within 15 minutes and uses an anterior nasal swab, with five drops of the sample applied to a test card. The results for COVID-19, influenza A, and influenza B are clearly shown through a color-coded display. Key features include suitability for individuals aged two years and older, rapid turnaround time, and simple self-collection without the need for specialized skills or equipment. This advancement helps ease pressure on healthcare facilities by allowing individuals to test at home, obtain quick results, and take appropriate actions such as isolation or seeking medical care at an earlier stage.

In June 2023, Avacta Group plc, a UK-based diagnostics and therapeutics company, acquired Coris Bioconcept SRL for an undisclosed amount. Through this acquisition, Avacta seeks to strengthen its rapid diagnostics portfolio by incorporating Coris Bioconcept’s professional-use lateral flow assays, including its COVID-19 antigen lateral flow test, and by utilizing Coris’s established manufacturing and distribution networks across Europe and international markets. Coris Bioconcept SRL is a Belgium-based diagnostic test manufacturer specializing in rapid lateral flow kits for respiratory, gastroenteric, and blood-borne pathogens.

Major companies operating in the COVID-19 antigen test market are F. Hoffmann-La Roche AG, Abbott Laboratories, Becton And Dickinson and Company, Laboratory Corporation Of America, PerkinElmer Inc., Quidel Corporation, SD Biosensor Inc., Diasorin S.P.A, Biosynex Swiss SA, iHealth Labs Inc., Everlywell Inc., JOYSBIO Biotechnology Co. Ltd., Mylab Discovery Solutions Pvt. Ltd., Access Bio Inc., RayBiotech Life Inc., CTK Biotech Inc., Artron Laboratories Inc., Princeton BioMeditech Corporation, ACON Laboratories Inc., BioLytical Laboratories Inc., BioNote Inc., Assure Tech (Hangzhou) Co. Ltd., ADS biotech Inc., ANP Technologies Inc., BTNX Inc., Cellspect Co.Ltd., Empowered Diagnostics LLC, GenBody Inc., Beijing Wantai Biologicalpharmacy Enterprise Co. Ltd.

Asia-Pacific was the largest region in the COVID-19 antigen test market in 2025. The regions covered in the COVID-19 antigen test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the COVID-19 antigen test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the COVID-19 antigen test market by increasing costs of imported reagents, lateral flow components, diagnostic consumables, and testing devices. Diagnostic labs and hospitals in North America and Europe are most affected due to reliance on imported kits, while Asia-Pacific faces higher manufacturing input costs. These tariffs are increasing test prices. However, they are also encouraging domestic kit production, regional manufacturing hubs, and supply chain localization.

The COVID-19 antigen test market research report is one of a series of new reports that provides COVID-19 antigen test market statistics, including COVID-19 antigen test industry global market size, regional shares, competitors with a COVID-19 antigen test market share, detailed COVID-19 antigen test market segments, market trends and opportunities, and any further data you may need to thrive in the COVID-19 antigen test industry. This COVID-19 antigen test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

COVID-19 is a contagious respiratory disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which infects the human respiratory system and can result in illnesses ranging from the common cold to severe respiratory conditions. A COVID-19 antigen test is a diagnostic method used to identify the presence of specific viral proteins from SARS-CoV-2 in a person’s respiratory sample. These tests typically use specimens collected through nasal or throat swabs.

The primary products and services associated with COVID-19 antigen testing include platforms, reagents and kits, and related services. Platforms refer to the technologies or systems used to perform these diagnostic tests. Sample types such as nasopharyngeal swabs, oropharyngeal swabs, and nasal swabs are commonly used across settings including clinics and hospitals, home care environments, diagnostic laboratories, and other end users.

The COVID-19 antigen test market consists of revenues earned by entities by providing services such as point-of-care testing (POC), telehealth services, travel testing services, and healthcare provider testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The COVID-19 antigen test market also includes sales of sample collection devices, extraction kits, buffers and solutions, and control materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.